Abeona Therapeutics Inc
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt dise… Read more
Abeona Therapeutics Inc (ABEO) - Total Assets
Latest total assets as of September 2025: $231.09 Million USD
Based on the latest financial reports, Abeona Therapeutics Inc (ABEO) holds total assets worth $231.09 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Abeona Therapeutics Inc - Total Assets Trend (1995–2024)
This chart illustrates how Abeona Therapeutics Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Abeona Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Abeona Therapeutics Inc's total assets of $231.09 Million consist of 92.6% current assets and 7.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 21.4% |
| Accounts Receivable | $1.65 Million | 1.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1995–2024)
This chart illustrates how Abeona Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Abeona Therapeutics Inc's current assets represent 92.6% of total assets in 2024, a decrease from 100.0% in 1995.
- Cash Position: Cash and equivalents constituted 21.4% of total assets in 2024, down from 88.7% in 1995.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1995.
- Asset Diversification: The largest asset category is accounts receivable at 1.5% of total assets.
Abeona Therapeutics Inc Competitors by Total Assets
Key competitors of Abeona Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Abeona Therapeutics Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Abeona Therapeutics Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Abeona Therapeutics Inc is currently not profitable relative to its asset base.
Abeona Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 9.74 | 6.12 | 2.33 |
| Quick Ratio | 9.53 | 6.12 | 2.33 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $193.95 Million | $ 94.23 Million | $ 55.78 Million |
Abeona Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Abeona Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.63 |
| Latest Market Cap to Assets Ratio | 1.86 |
| Asset Growth Rate (YoY) | 70.2% |
| Total Assets | $108.93 Million |
| Market Capitalization | $202.79 Million USD |
Valuation Analysis
Above Book Valuation: The market values Abeona Therapeutics Inc's assets above their book value (1.86 x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Abeona Therapeutics Inc's assets grew by 70.2% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Abeona Therapeutics Inc (1995–2024)
The table below shows the annual total assets of Abeona Therapeutics Inc from 1995 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $108.93 Million | +70.20% |
| 2023-12-31 | $64.00 Million | -0.33% |
| 2022-12-31 | $64.21 Million | -19.31% |
| 2021-12-31 | $79.59 Million | -47.36% |
| 2020-12-31 | $151.20 Million | -32.31% |
| 2019-12-31 | $223.38 Million | +28.09% |
| 2018-12-31 | $174.40 Million | -2.44% |
| 2017-12-31 | $178.77 Million | +60.97% |
| 2016-12-31 | $111.06 Million | +38.73% |
| 2015-12-31 | $80.06 Million | +382.78% |
| 2014-12-31 | $16.58 Million | +2605.06% |
| 2013-12-31 | $613.00K | -64.57% |
| 2012-12-31 | $1.73 Million | -54.29% |
| 2011-12-31 | $3.79 Million | -56.85% |
| 2010-12-31 | $8.77 Million | +454.07% |
| 2009-12-31 | $1.58 Million | -62.05% |
| 2008-12-31 | $4.17 Million | -54.41% |
| 2007-12-31 | $9.15 Million | +42.37% |
| 2006-12-31 | $6.43 Million | -10.91% |
| 2005-12-31 | $7.21 Million | -34.96% |
| 2004-12-31 | $11.09 Million | -6.10% |
| 2003-12-31 | $11.81 Million | -39.39% |
| 2002-12-31 | $19.49 Million | -23.54% |
| 2001-12-31 | $25.49 Million | -16.51% |
| 2000-12-31 | $30.53 Million | +563.61% |
| 1999-12-31 | $4.60 Million | +91.67% |
| 1998-12-31 | $2.40 Million | +65.86% |
| 1997-12-31 | $1.45 Million | -70.64% |
| 1996-12-31 | $4.93 Million | +131.47% |
| 1995-12-31 | $2.13 Million | -- |